Remed Signs a 5-Year ESWT Contract with Shunbo Medical

On April 8th, Korean electronic medication specialist company Remed, under the leadership of Geun-Yong Lee, announced a significant development. They have entered into a five-year contract with Chinese company Shunbo Medical for the supply of Extracorporeal Shock Wave Therapy (ESWT) products.

Remed, known for its involvement in research and development, production, and sales of medical devices, has been making strategic moves in the market. In July 2023, the company secured a contract to supply its flagship products, the Neuro Magnetic Stimulator (NMS) and the Transcranial Magnetic Stimulator (TMS), utilizing the SKD (Semi Complete Knock Down) method.

The scale of this latest supply contract involves a minimum order quantity (MOQ) of 1000 units for three additional Extracorporeal Shock Wave Therapy devices. This supply will be spread over five years, employing the same SKD method utilized previously.

The Extracorporeal Shock Wave Therapy device covered by this contract targets damaged tissues in the body, providing treatment for musculoskeletal degenerative lesions, tendon damage resulting from excessive exercise, and calcification around joints. According to the company, this product offers precise delivery of shock waves to address musculoskeletal disorders, facilitating non-surgical treatment for joint conditions or injuries. It presents an alternative to traditional conservative therapies such as physical therapy and injections, offering fundamental pain relief.

A spokesperson for Remed commented on the additional contract, expressing confidence in their products in overseas markets. They emphasized their commitment to expanding their presence in the Chinese market by expediting the localization of production and obtaining necessary approvals.